RECRUITING

Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People with Subcortical Stroke

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to verify whether the use of deep brain stimulation can improve motor function of the hand and arm and speech abilities for people following a stroke. Participants will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days. Results of this study will provide the foundation for future studies evaluating the efficacy of a minimally-invasive neuro-technology that can be used in clinical neuro-rehabilitation programs to restore speech and upper limb motor functions in people with subcortical strokes, thereby increasing independence and quality of life.

Official Title

Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People with Subcortical Stroke

Quick Facts

Study Start:2024-11
Study Completion:2029-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06303869

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Participants must have suffered a single, ischemic, or hemorrhagic stroke more than 6 months before the time of enrollment with dysarthria as a result.
  2. 2. Participants must be between the ages of 18 and 75 years old. (Participants outside this age range may be at an increased medical risk and have an increased risk of fatigue during testing).
  3. 3. Native English speaker.
  4. 4. Patients with moderate to severe dysarthria (50-89% intelligibility in the Assessment of Intelligibility of Dysarthric Speech test).
  1. 1. Patients who refuse participation in the study.
  2. 2. Patients with gross anatomical variances in MR imaging or cerebral vascular accidents involving thalamic and cerebellar areas.
  3. 3. Patients with no clinical condition to undergo DBS implantation or highly dependent on anticoagulation therapy.
  4. 4. Patients who cannot undergo pre-operative MRIs or could not complete the pre-operative assessments.
  5. 5. Participants must not have any serious disease or disorder (ex. neurological condition other than stroke, cancer, severe cardiac or respiratory disease, renal failure, etc.) or cognitive impairments that could affect their ability to participate in this study.
  6. 6. Female participants of child-bearing age must not be pregnant, planning to become pregnant for the next 9 months, or breast feeding.
  7. 7. Participants must not be receiving anticoagulants.
  8. 8. Severe claustrophobia.
  9. 9. Participants must not be on anti-spasticity or anti-epileptic medications for the duration of the study.
  10. 10. Participants who have been deemed inappropriate for participation based upon results from the Brief Symptoms Inventory (BSI-18) and discussions with the Principal Investigator and a study physician
  11. 11. Evaluation to sign consent form score \<12.
  12. 12. MRI contraindications (excluding subjects who are pregnant, who have metal in any portion of their body, have medical complications, cardiac pacemaker, cochlear implant, aneurysm clip, certain IUDs, or known problems of claustrophobia).
  13. 13. Medications with common cognitive side-effects.
  14. 14. Bleeding disorders or platelet dysfunction (e.g., from regular aspirin usage).
  15. 15. Patients must not have any lesions in the lower motoneuron causing flaccid dysarthria.

Contacts and Locations

Study Contact

Cierra Clark, MS
CONTACT
240-441-4216
cic27@pitt.edu
Elvira Pirondini, PhD
CONTACT
412-636-0595
elvirap@pitt.edu

Principal Investigator

Jorge Gonzalez-Martinez, MD/PhD
PRINCIPAL_INVESTIGATOR
University of Pittsburgh

Study Locations (Sites)

University of Pittsburgh
Pittsburgh, Pennsylvania, 15213
United States

Collaborators and Investigators

Sponsor: Jorge Gonzalez-Martinez

  • Jorge Gonzalez-Martinez, MD/PhD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11
Study Completion Date2029-12

Study Record Updates

Study Start Date2024-11
Study Completion Date2029-12

Terms related to this study

Additional Relevant MeSH Terms

  • Stroke
  • Brain Disease
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Cardiovascular Diseases